Enanta Pharmaceuticals, Inc.

NasdaqGS:ENTA Stock Report

Market Cap: US$122.9m

Enanta Pharmaceuticals Future Growth

Future criteria checks 1/6

Enanta Pharmaceuticals's earnings are forecast to decline at 6.2% per annum while its annual revenue is expected to grow at 11% per year. EPS is expected to grow by 1.6% per annum. Return on equity is forecast to be -44.3% in 3 years.

Key information

-6.2%

Earnings growth rate

1.61%

EPS growth rate

Biotechs earnings growth23.9%
Revenue growth rate11.0%
Future return on equity-44.28%
Analyst coverage

Good

Last updated16 May 2025

Recent future growth updates

Analysts Have Been Trimming Their Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Price Target After Its Latest Report

Nov 30
Analysts Have Been Trimming Their Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Price Target After Its Latest Report

Here's What Analysts Are Forecasting For Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) After Its Third-Quarter Results

Aug 08
Here's What Analysts Are Forecasting For Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) After Its Third-Quarter Results

Recent updates

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Not Doing Enough For Some Investors As Its Shares Slump 27%

Mar 31
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Not Doing Enough For Some Investors As Its Shares Slump 27%

Enanta Pharmaceuticals, Inc.'s (NASDAQ:ENTA) Shares Bounce 55% But Its Business Still Trails The Industry

Feb 14
Enanta Pharmaceuticals, Inc.'s (NASDAQ:ENTA) Shares Bounce 55% But Its Business Still Trails The Industry

Analysts Have Been Trimming Their Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Price Target After Its Latest Report

Nov 30
Analysts Have Been Trimming Their Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Price Target After Its Latest Report

Benign Growth For Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Underpins Stock's 27% Plummet

Nov 27
Benign Growth For Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Underpins Stock's 27% Plummet

Health Check: How Prudently Does Enanta Pharmaceuticals (NASDAQ:ENTA) Use Debt?

Oct 05
Health Check: How Prudently Does Enanta Pharmaceuticals (NASDAQ:ENTA) Use Debt?

Here's What Analysts Are Forecasting For Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) After Its Third-Quarter Results

Aug 08
Here's What Analysts Are Forecasting For Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) After Its Third-Quarter Results

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Held Back By Insufficient Growth Even After Shares Climb 26%

Jul 24
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Held Back By Insufficient Growth Even After Shares Climb 26%

Is Enanta Pharmaceuticals (NASDAQ:ENTA) Using Debt In A Risky Way?

Jun 19
Is Enanta Pharmaceuticals (NASDAQ:ENTA) Using Debt In A Risky Way?

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Just Released Its Second-Quarter Earnings: Here's What Analysts Think

May 09
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Just Released Its Second-Quarter Earnings: Here's What Analysts Think

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Shares Fly 27% But Investors Aren't Buying For Growth

Mar 05
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Shares Fly 27% But Investors Aren't Buying For Growth

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Feb 12
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Time To Worry? Analysts Are Downgrading Their Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Outlook

Aug 13
Time To Worry? Analysts Are Downgrading Their Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Outlook

We Discuss Why Enanta Pharmaceuticals, Inc.'s (NASDAQ:ENTA) CEO Compensation May Be Closely Reviewed

Feb 24
We Discuss Why Enanta Pharmaceuticals, Inc.'s (NASDAQ:ENTA) CEO Compensation May Be Closely Reviewed

Things Look Grim For Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) After Today's Downgrade

Feb 08
Things Look Grim For Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) After Today's Downgrade

Downgrade: Here's How Analysts See Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Performing In The Near Term

Nov 25
Downgrade: Here's How Analysts See Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Performing In The Near Term

Is Enanta Pharmaceuticals (NASDAQ:ENTA) Weighed On By Its Debt Load?

Oct 25
Is Enanta Pharmaceuticals (NASDAQ:ENTA) Weighed On By Its Debt Load?

Enanta starts mid-stage trial of EDP-938 for RSV infection

Oct 03

Enanta Pharma FQ3 2022 Earnings Preview

Aug 07

Enanta potential COVID drug shows safety in healthy people in early-stage trial

Jul 29

Enanta Pharmaceuticals (NASDAQ:ENTA) Has Debt But No Earnings; Should You Worry?

Jul 04
Enanta Pharmaceuticals (NASDAQ:ENTA) Has Debt But No Earnings; Should You Worry?

Enanta: Slow Drip

May 17

Earnings and Revenue Growth Forecasts

NasdaqGS:ENTA - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
9/30/202763-115-73N/A5
9/30/202661-105-98-717
9/30/202562-83-83-645
3/31/202564-96-82-55N/A
12/31/202467-105-96-71N/A
9/30/202468-116-97-79N/A
6/30/202472-115-100-90N/A
3/31/202473-132-113-107N/A
12/31/202374-138-99-93N/A
9/30/202379-134-112-103N/A
6/30/202381-132-106-97N/A
3/31/202381-125-102-95N/A
12/31/202282-121-112-107N/A
9/30/202286-122-87-85N/A
6/30/202289-120-91-90N/A
3/31/202292-112-91-90N/A
12/31/202193-101-69-68N/A
9/30/202197-79-71-70N/A
6/30/202197-84-65-64N/A
3/31/202194-74-40-39N/A
12/31/2020102-58-21-20N/A
9/30/2020122-3667N/A
6/30/202015023031N/A
3/31/2020176243538N/A
12/31/2019188344854N/A
9/30/2019205466671N/A
6/30/2019221658591N/A
3/31/2019234788893N/A
12/31/201823886N/A55N/A
9/30/201820772N/A29N/A
6/30/201821581N/A58N/A
3/31/201816652N/A49N/A
12/31/201713134N/A54N/A
9/30/201710318N/A53N/A
6/30/201740-21N/A-7N/A
3/31/201746-13N/A-4N/A
12/31/201650-10N/A9N/A
9/30/20168822N/A36N/A
6/30/20169029N/A36N/A
3/31/20168733N/A23N/A
12/31/201513263N/A112N/A
9/30/201516179N/A77N/A
6/30/201514968N/A74N/A
3/31/2015180116N/A123N/A
12/31/201412482N/A20N/A
9/30/20144834N/A20N/A
6/30/20144635N/A23N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: ENTA is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: ENTA is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: ENTA is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: ENTA's revenue (11% per year) is forecast to grow faster than the US market (8.5% per year).

High Growth Revenue: ENTA's revenue (11% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: ENTA is forecast to be unprofitable in 3 years.

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/18 11:17
End of Day Share Price 2025/05/16 00:00
Earnings2025/03/31
Annual Earnings2024/09/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Enanta Pharmaceuticals, Inc. is covered by 19 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Brian SkorneyBaird
Geoffrey MeachamBarclays
Patrick TrucchioBerenberg